NeuroSense Therapeutics Ltd. (NASDAQ:NRSN – Get Free Report)’s share price shot up 3.3% on Friday . The company traded as high as $0.55 and last traded at $0.53. 388,555 shares traded hands during mid-day trading, a decline of 22% from the average session volume of 498,123 shares. The stock had previously closed at $0.51.
NeuroSense Therapeutics Stock Performance
The company has a quick ratio of 2.80, a current ratio of 2.52 and a debt-to-equity ratio of 0.04. The firm has a market cap of $5.81 million, a price-to-earnings ratio of -0.41 and a beta of -0.63. The business’s 50-day simple moving average is $0.61 and its two-hundred day simple moving average is $1.12.
Institutional Inflows and Outflows
NeuroSense Therapeutics Company Profile
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis.
- Five stocks we like better than NeuroSense Therapeutics
- What Does a Stock Split Mean?
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Upcoming IPO Stock Lockup Period, Explained
- MarketBeat Week in Review – 11/13 – 11/17
- P/E Ratio Calculation: How to Assess Stocks
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for NeuroSense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroSense Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.